| New from NCI |
| Immunotherapy Side Effects |
 |
|
We have two new pages and one updated page about side effects you might have during treatment with immunotherapy. Learn more about organ inflammation, flu-like symptoms, and skin and nail changes, including signs to look for and what to do if they occur. |
| Slowing the Progression of Smoldering Myeloma |
 |
|
Read about clinical trial results that show the drug lenalidomide (Revlimid) may delay the development of multiple myeloma in people with smoldering myeloma that is at high risk of turning into cancer. |
Venetoclax Approved for Chronic Lymphocytic Leukemia
The Food and Drug Administration (FDA) has approved venetoclax (Venclexta) for use with obinutuzumab (Gazyva) as an initial treatment for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. |
| The Childhood Cancer Data Initiative: Why Data Sharing is Essential to Progress |
 |
|
Learn about this initiative to speed progress against cancer in children, adolescents, and young adults by establishing more efficient ways to share and use childhood cancer data. |
Drugs Approved for Childhood Cancer
FDA has approved more than two dozen drugs to treat childhood cancers. See the complete list, including those supported by data from NCI-sponsored research.
|
| Drug Information Updates |
Pembrolizumab Use in Head and Neck Cancer
We’ve updated our drug information summary on pembrolizumab (Keytruda) to reflect FDA’s expanded approval of the drug in squamous cell carcinoma of the head and neck. Pembrolizumab is now approved for use as first-line treatment in certain patients with metastatic or recurrent disease. |
